Therapy Areas: Diabetes
Curacle and Théa Ink Licensing and Collaboration Agreement for the Development and Commercialization of Orally Administered Treatment for Diabetic Macular Edema and Wet-AMD
27 October 2021 - - Korea-based biopharmaceutical company Curacle has entered into an exclusive license and collaboration agreement with Théa Open Innovation, the sister company of European ophthalmic company Théa, for the development and commercialization of Curacle's CU06-RE, that has the potential to become the first orally administered treatment for diabetic macular edema and wet age-related macular degeneration (wet-AMD), the company said.

Under the terms of the agreement, Curacle will receive an upfront payment of USD 6m and could receive up to an additional USD 157.5m in potential development, regulatory and sales milestones, as well as royalties on sales if CU06-RE is successfully developed, which will entitle Curacle to receive up to USD 2bn in total payments.

Théa and Curacle will closely collaborate on the clinical development of this novel oral drug. Curacle will be responsible for the Phase I and II clinical studies with TOI providing both financial and infrastructure support.

Further, under the terms of the agreement, Curacle will retain the marketing rights in all Asia countries while Théa will have the marketing rights in all other countries around the world.

Curacle (KOSDAQ) is a Korea-based clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapeutics for the treatment of aged-related vascular and intractable metabolic diseases and cancers.

Founded in 2016, Curacle has developed the disease-expressive screening system, SOLVADYS Platform, which screens substances that directly convert the pathological characteristics of the capillary vessels such as leakage, inflammatory activation, and apoptosis using human organ-specific primary endothelial cells.

The SOLVADYS Platform dramatically improves the efficacy and ease of administration for acute and chronic conditions that are accompanied by vascular leakage, inflammation and loss of endothelial cells.

Théa is a leading independent European pharmaceutical company specialized in the research, development, and commercialization of eye-care products.

Based in Clermont-Ferrand, France, this family-owned company has continued to expand by opening more than 30 affiliates and offices in Europe, Russia, North Africa, North and South America. Its products are available in 75 countries.

Théa Open Innovation is a sister company of Théa. TOI's mission is to set up partnerships with companies and universities to help bring the most innovative products in ophthalmology to the market.


Related Headlines